Treatment with intra-arterial (IA) gemcitabine led to an improvement in overall survival (OS) compared with continued treatment with intravenous (IV) gemcitabine plus nab-paclitaxel (Abraxane) in patients with locally advanced pancreatic cancer following sequential treatment with IV gemcitabine, nab-paclitaxel, and radiotherapy, according to data from the first interim analysis of phase 3 TIGeR-PaC trial (NCT03257033).
Data presented at the 2023 ESMO World Congress on Gastrointestinal Cancer showed that patients treated with IA gemcitabine (n = 23) experienced a median OS of 15.7 months compared with 10.1 months for those who continue with IV gemcitabine and nab-paclitaxel (n = 22; HR, 0.48; 95% CI, 0.20-1.12; P < .08).